Lilly's Omvoh meets primary endpoint in pediatric colitis trial
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) reported positive one-year results from its Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




